Alfa Wassermann S.p.a.

Alfasigma S.p.a.

Villiam Zamboni

Giuseppe Claudio Viscomi

Ernesto Palazzini

Maria Rosaria Pantaleo

Maria Barbanti

Claudia Baldazzi

The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.

Gastroresistant pharmaceutical formulations containing rifaximin

The prevention and therapy of pulmonary embolism with pharmaceutical compositions containing low molecular weight dermatan sulfate is described. These pharmaceutical compositions are administered by subcutaneous, intramuscular or intravenous route at a daily dosage between 200 and 3000 mgs of active principle. The low molecular weight dermatan sulfate preferred in carrying out the invention has an average molecular weight equal to 5500.+-.1100 Daltons and is obtained by depolymerization of the dermatan sulfate of natural origin in the presence of hydrogen peroxide and cupric ions.

Pharmaceutical compositions containing low molecular weight dermatan

Growing community of inventors

Bologna, Italy

Villiam Zamboni